(NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of course, a lot of this was due to an unprecedented situation -- the COVID-19 pandemic -- and two products to address it: Pfizer's coronavirus vaccine and treatment.

As demand for these treatments dropped in later pandemic times, though, it was clear Pfizer needed a new growth driver. And the big pharma company announced that a key driver of that growth would be oncology drugs. To increase its presence in that area, Pfizer last year acquired oncology specialist Seagen, a company focused on antibody-drug conjugates (ADCs). These allow for the delivery of potent treatments directly to tumor cells, in order to limit damage to normal cells.

This week, Pfizer reported second-quarter earnings; this marks its second full quarter of earnings that include Seagen products. Is Pfizer winning its $43 billion bet on the oncology specialist? Let's find out.

Continue reading

Source Fool.com